XyloCor

Gene therapy developer XyloCor adds $22.6M to expand clinical trial plans

With the extension to its Series A financing, XyloCor plans a clinical trial testing its gene therapy as an adjunct to coronary artery bypass graft surgery. A study in refractory angina is already underway.

By Frank Vinluan

BioPharma, Startups

XyloCor closes $17M Series A round to develop gene therapy for refractory angina

The Philadelphia-based company has an IND open with the FDA and plans to begin its clinical trial in the first half of next year.

By Alaric DeArment